{"denoms":[{"counts":[{"groupId":"BG000","value":"3"}],"units":"Participants"}],"groups":[{"description":"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nofatumumab: Given IV\n\nbortezomib: Given SC\n\nlaboratory biomarker analysis: Correlative studies","id":"BG000","title":"Treatment (Monoclonal Antibody Therapy)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"1.8","value":"62.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"All treated and eligible patients"}